Can patients be anticoagulated after intracerebral hemorrhage? A decision analysis

Stroke

Volumn 34, Issue 7, 2003, Pages 1710-1716

  Eckman, Mark H ^a,c   Rosand, Jonathan ^b   Knudsen, Katherine A ^b   Singer, Daniel E ^b   Greenberg, Steven M ^b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

Atrial fibrillation; Decision support techniques; Intracerebral hemorrhage; Markov chains; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; WARFARIN;

AGED; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BRAIN HEMORRHAGE; CASE REPORT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FUNCTIONAL DISEASE; HEART ATRIUM FIBRILLATION; HEMISPHERE; HUMAN; INCIDENCE; LIFE EXPECTANCY; MALE; MEDICAL DECISION MAKING; MODEL; MORTALITY; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RECURRENT DISEASE; RISK FACTOR; THROMBOEMBOLISM; TREATMENT OUTCOME;

AGED; ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; CEREBRAL HEMORRHAGE; COHORT STUDIES; DECISION SUPPORT TECHNIQUES; FIBRINOLYTIC AGENTS; HUMANS; INTRACRANIAL THROMBOSIS; MALE; MARKOV CHAINS; QUALITY-ADJUSTED LIFE YEARS; RISK; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; WARFARIN;

EID: 0038168516     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000078311.18928.16     Document Type: Article

References (39)

1. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154:1449-1457.
2. Hart RG, Boop BS, Anderson DC. Oral anticoagulants and intracranial hemorrhage: facts and hypotheses. Stroke. 1995;26:1471-1477.
3. Mathiesen T, Benediktsdottir K, Johnsson H, Lindqvist M, von Holst H. Intracranial traumatic and non-traumatic haemorrhagic complications of warfarin treatment. Acta Neurol Scand. 1995;91:208-214.
4. Franke CL, de Jonge J, van Swieten JC, Op de Coul AA, van Gijn J. Intracerebral hematomas during anticoagulant treatment. Stroke. 1990;21:726-730.
5. Wong KS. Risk factors for early death in acute ischemic stroke and intracerebral hemorrhage: a prospective hospital-based study in Asia: Asian Acute Stroke Advisory Panel. Stroke. 1999;30:2326-2330.
6. Detsky A, Naglie G, Krahn M, Naimark D, Redelmeier D. Primer on medical decision analysis, part 1: getting started. Med Decis Making. 1997;17:123-125.
7. Eckman MH, Levine HJ, Salem DN, Pauker SG. Making decisions about antithrombotic therapy in heart disease: decision analytic and cost-effectiveness issues. Chest. 1998;114(suppl):699S-714S.
8. Eckman MH, Pauker SG. Decision analytic issues in the management of atrial fibrillation. In: Falk RH, Podrid PJ, eds. Atrial Fibrillation: Mechanisms and Management. Philadelphia, Pa: Lippincott-Raven Publishers; 1997:469-488.
9. Thomson R, Robinson A, Greenaway J, Lowe P. Development and description of a decision analysis based decision support tool for stroke prevention in atrial fibrillation. Qual Health Care, 2002;11:25-31.
10. Man-Son-Hing M, Nichol G, Lau A, Laupacis A. Choosing anti-thrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med. 1999;159:677-685.
11. Man-Son-Hing M, Laupacis A. Balancing the risks of stroke and upper gastrointestinal tract bleeding in older patients with atrial fibrillation. Arch Intern Med. 2002;162:541-550.
12. O'Donnell HC, Rosand J, Knudsen KA, et al. Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage. N Engl J Med. 2000;342:240-245.
13. Bailey RD, Hart RG, Benavente O, Pearce LA. Recurrent brain hemorrhage is more frequent than ischemic stroke after intracranial hemorrhage. Neurology. 2001;56:773-777.
14. Wijdicks EF, Schievink WI, Brown RD, Mullany CJ. The dilemma of discontinuation of anticoagulation therapy for patients with intracranial hemorrhage and mechanical heart valves. Neurosurgery. 1998;42:769-773.
15. Lau J, Kassirer JP, Pauker SG. Decision Maker 3.0: improved decision analysis by personal computer. Med Decis Making. 1983;3:39-43.
16. Gage BF, Cardinalli AB, Owens DK. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch Intern Med. 1996;156:1829-1836.
17. Wilson JT, Pettigrew LE, Teasdale GM. Structured interviews for the Glasgow Outcome Scale and the extended Glasgow Outcome Scale: guidelines for their use. J Neurotrauma. 1998;15:573-585.
18. Tengs TO, Yu M, Luistro E. Health-related quality of life after stroke: a comprehensive review. Stroke. 2001;32:964-972.
19. Wintzen AR, de Jonge H, Loeliger EA, Bots GT. The risk of intracerebral hemorrhage during oral anticoagulant treatment: a population study. Ann Neurol. 1984;16:553-558.
20. Fogelholm R, Eskola K, Kiminkinen T, Kunnamo I. Anticoagulant treatment as a risk factor for primary intracerebral hemorrhage. J Neurol Neurosurg Psychiatry. 1992;55:1121-1124.
21. Albers GW, Sherman DG, Gress DR, Paulseth JE, Petersen P. Stroke prevention in nonvalvular atrial fibrillation: a review of prospective randomized trials. Ann Neurol. 1991;30:511-518.
22. Lai SM, Alter M, Friday G, Sobel E. Prognosis for survival after an initial stroke. Stroke. 1995;26:2011-2015.
23. National Center for Health Statistics: Vital Statistics in the United States, Volume II: Mortality. Washington, DC: Public Health Service, US Government Printing Office; 1988. Part A.
24. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999;131:492-501.
25. He J, Whelton PK, Vu B, Klag MJ. Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials. JAMA. 1998;280:1930-1935.
26. Rosand J, Hylek EM, O'Donnell HC, Greenberg SM. Warfarin-associated hemorrhage and cerebral amyloid angiopathy: a genetic and pathologic study. Neurology. 2000;55:947-951.
27. Woo D, Sauerbeck LR, Kissela BM, et al. Genetic and environmental risk factors for intracerebral hemorrhage: preliminary results of a population-based study. Stroke. 2002;33:1190-1195; discussion 1195-1196.
28. Knudsen KA, Rosand J, Karluk D, Greenberg SM. Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria. Neurology. 2001;56:537-539.
29. Bae H, Jeong D, Doh J, Lee K, Yun I, Byun B. Recurrence of bleeding in patients with hypertensive intracerebral hemorrhage. Cerebrovasc Dis. 1999;9:102-108.
30. Arakawa S, Saku Y, Ibayashi S, Nagao T, Fujishima M. Blood pressure control and recurrence of hypertensive brain hemorrhage. Stroke. 1998;29:1806-1809.
31. Greenberg SM, O'Donnell HC, Schaefer PW, Kraft E. MRI detection of new hemorrhages: potential marker of progression in cerebral amyloid angiopathy. Neurology. 1999;53:1135-1138.
32. McCarron MO, Nicoll JA. Apolipoprotein E genotype and cerebral amyloid angiopathy-related hemorrhage. Ann N Y Acad Sci. 2000;903:176-179.
33. Tabrizi AR, Freeman BD, Buchman TG, Zehnbauer BA. Genetic susceptibility to hemorrhagic complications during warfarin therapy. Surgery. 2001;129:645-646.
34. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 1999;353:717-719.
35. Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA. 2002;287:1690-1698.
36. The efficacy of aspirin in patients with atrial fibrillation: analysis of pooled data from 3 randomized trials: the Atrial Fibrillation Investigators. Arch Intern Med. 1997;157:1237-1240.
37. Penado S, Cano M, Acha O, Hernandez JL, Riancho JA. Stroke severity in patients with atrial fibrillation. Am J Med. 2002;112:572-574.
38. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in out-patients taking warfarin. Ann Intern Med. 1994;120:897-902.
39. Bleeding during antithrombotic therapy in patients with atrial fibrillation: the Stroke Prevention in Atrial Fibrillation Investigators. Arch Intern Med. 1996;156:409-416.